drugset / Trial / NCT00826930

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

NCT00826930

Phase 1 Terminated 1 enrolled Diffusion Pharmaceuticals Inc
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma. The proposed clinical indication for TSC is a radiation sensitizer for the treatment of cancerous tumors.

Timeline

Start
2009-03
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Trans Sodium Crocetinate Other / unclassified 0.5 mg/kg Intravenous
Subject Trans Sodium Crocetinate Other / unclassified 0.75 mg/kg Intravenous
Subject Trans Sodium Crocetinate Other / unclassified 1 mg/kg Intravenous

Indications